Literature DB >> 11563082

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs.

T Cihlar, E S Ho, D C Lin, A S Mulato.   

Abstract

hOAT1 is a renal membrane protein able to efficiently transport acyclic nucleoside phosphonates (ANPs). When expressed in CHO cells, hOAT1 mediates the uptake and cytotoxicity of ANPs suggesting that it plays an active role in the nephrotoxicity associated with cidofovir CMV therapy and high-dose adefovir HIV therapy. Although efficiently transported by hOAT1, tenofovir did not show any significant cytotoxicity in isolated human proximal tubular cells, which correlates with the lack of nephrotoxicity observed in HIV-infected patients on prolonged tenofovir therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563082     DOI: 10.1081/NCN-100002341

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  68 in total

1.  Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*.

Authors:  Gabriel Birkus; Miroslav Hájek; Pavel Kramata; Ivan Votruba; Antonín Holý; Berta Otová
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Analysis of three-dimensional systems for developing and mature kidneys clarifies the role of OAT1 and OAT3 in antiviral handling.

Authors:  Megha A Nagle; David M Truong; Ankur V Dnyanmote; Sun-Young Ahn; Satish A Eraly; Wei Wu; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

Review 3.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

4.  In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

Authors:  Francesc Vidal; Joan Carles Domingo; Jordi Guallar; Maria Saumoy; Begoña Cordobilla; Rainel Sánchez de la Rosa; Marta Giralt; Maria Luisa Alvarez; Miguel López-Dupla; Ferran Torres; Francesc Villarroya; Tomas Cihlar; Pere Domingo
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 5.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

Review 6.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

7.  Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.

Authors:  James J McSharry; Mark R Deziel; Kris Zager; Qingmei Weng; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

Review 8.  Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.

Authors:  Melanie R Nicol; Joseph A Corbino; Mackenzie L Cottrell
Journal:  J Clin Pharmacol       Date:  2018-06-14       Impact factor: 3.126

9.  Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.

Authors:  Amit Khatri; Sandeep Dutta; Martin Dunbar; Thomas Podsadecki; Roger Trinh; Walid Awni; Rajeev Menon
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

10.  Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.

Authors:  Mio Tanaka; Fumitaka Suzuki; Yuya Seko; Tasuku Hara; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2013-03-26       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.